Stem definition | Drug id | CAS RN |
---|---|---|
steroids, progestogens | 1962 | 68-22-4 |
Dose | Unit | Route |
---|---|---|
2.50 | mg | P |
5 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.02 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 64 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
May 21, 1962 | FDA | ORTHO MCNEIL PHARM |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dilatation intrahepatic duct acquired | 230.26 | 47.86 | 26 | 252 | 62 | 2357745 |
Vaginal haemorrhage | 155.25 | 47.86 | 31 | 247 | 4949 | 2352858 |
Purpura | 131.22 | 47.86 | 23 | 255 | 1787 | 2356020 |
Hepatotoxicity | 128.48 | 47.86 | 25 | 253 | 3456 | 2354351 |
Venoocclusive liver disease | 125.34 | 47.86 | 19 | 259 | 589 | 2357218 |
Rash maculo-papular | 117.53 | 47.86 | 24 | 254 | 4228 | 2353579 |
Rectal haemorrhage | 104.28 | 47.86 | 23 | 255 | 5833 | 2351974 |
Rash erythematous | 103.81 | 47.86 | 23 | 255 | 5953 | 2351854 |
Melaena | 100.66 | 47.86 | 21 | 257 | 4085 | 2353722 |
Haemorrhage | 94.73 | 47.86 | 24 | 254 | 11015 | 2346792 |
Hepatic adenoma | 88.56 | 47.86 | 11 | 267 | 70 | 2357737 |
Cholestasis of pregnancy | 83.79 | 47.86 | 11 | 267 | 114 | 2357693 |
Liver function test abnormal | 82.88 | 47.86 | 20 | 258 | 7470 | 2350337 |
Alanine aminotransferase increased | 79.62 | 47.86 | 22 | 256 | 14010 | 2343797 |
Haemoglobin decreased | 74.02 | 47.86 | 22 | 256 | 18129 | 2339678 |
Platelet count increased | 57.89 | 47.86 | 12 | 266 | 2225 | 2355582 |
Cerebral venous thrombosis | 48.32 | 47.86 | 8 | 270 | 430 | 2357377 |
Ovarian atrophy | 48.01 | 47.86 | 6 | 272 | 40 | 2357767 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | G03AC01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens |
ATC | G03DC02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Estren derivatives |
ATC | G03AA05 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
ATC | G03AB04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
ATC | G03FA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations |
ATC | G03FB05 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, sequential preparations |
FDA Chemical/Ingredient | N0000011301 | Progesterone Congeners |
FDA EPC | N0000175602 | Progestin |
CHEBI has role | CHEBI:49326 | synthetic oral contraceptive |
MeSH PA | D003270 | Contraceptive Agents |
MeSH PA | D003271 | Contraceptive Agents, Female |
MeSH PA | D000080066 | Contraceptive Agents, Hormonal |
MeSH PA | D003278 | Contraceptives, Oral, Hormonal |
MeSH PA | D003280 | Contraceptives, Oral, Synthetic |
MeSH PA | D012102 | Reproductive Control Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Contraception | indication | 13197004 | |
Female hypogonadism syndrome | indication | 16041008 | |
Dysfunctional uterine bleeding | indication | 19155002 | |
Atrophic vaginitis | indication | 52441000 | |
Primary ovarian failure | indication | 65846009 | |
Secondary physiologic amenorrhea | indication | 86030004 | |
Acne vulgaris | indication | 88616000 | |
Postmenopausal osteoporosis | indication | 102447009 | |
Endometriosis | indication | 129103003 | |
Menopausal flushing | indication | 198436008 | |
Atrophic vulva | indication | 248861000 | DOID:14275 |
Menorrhagia | indication | 386692008 | |
Amenorrhea | off-label use | 14302001 | DOID:13938 |
Polycystic ovaries | off-label use | 69878008 | |
Dysmenorrhea | off-label use | 266599000 | |
Abnormal uterine bleeding unrelated to menstrual cycle | off-label use | 312984006 | |
Heart valve disorder | contraindication | 368009 | DOID:4079 |
Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
Hypocalcemia | contraindication | 5291005 | |
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Depressive disorder | contraindication | 35489007 | |
Chloasma | contraindication | 36209000 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Body fluid retention | contraindication | 43498006 | |
Thrombosis of retinal vein | contraindication | 46085004 | |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Chronic heart failure | contraindication | 48447003 | |
Dementia | contraindication | 52448006 | |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Benign mammary dysplasia | contraindication | 57993004 | |
Obstructive hyperbilirubinemia | contraindication | 59848001 | |
Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Breast lump | contraindication | 89164003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Malignant neoplasm of liver | contraindication | 93870000 | DOID:3571 |
Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
Deep venous thrombosis | contraindication | 128053003 | |
Liver function tests abnormal | contraindication | 166603001 | |
Mammography abnormal | contraindication | 168750009 | |
Angina pectoris | contraindication | 194828000 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Cerebrovascular accident | contraindication | 230690007 | |
Pulmonary thromboembolism | contraindication | 233935004 | |
Thrombophilia | contraindication | 234467004 | DOID:2452 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Cholestasis of pregnancy | contraindication | 235888006 | |
Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
Chorea | contraindication | 271700006 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Functional visual loss | contraindication | 313165001 | |
Malignant tumor of cervix | contraindication | 363354003 | DOID:4362 |
Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
Thromboembolic disorder | contraindication | 371039008 | |
Cardiovascular event risk | contraindication | 395112001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Estrogen receptor positive tumor | contraindication | 416053008 | |
Porphyria | contraindication | 418470004 | |
Optic disc edema | contraindication | 423341008 | DOID:146 |
Family history of malignant neoplasm of breast | contraindication | 429740004 | |
Hypertensive urgency | contraindication | 443482000 | |
Carcinoma of female breast | contraindication | 447782002 | |
Smokes tobacco daily | contraindication | 449868002 | |
Nonspecific Abnormal Papanicolaou Smear of Cervix | contraindication | ||
Major Surgery with Prolonged Post-Operative Immobilization | contraindication |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Progesterone receptor | Nuclear hormone receptor | AGONIST | ED50 | 11.26 | WOMBAT-PK | CHEMBL | |||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.62 | DRUG MATRIX | |||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 6.71 | DRUG MATRIX | |||||
Estrogen receptor | Nuclear hormone receptor | Ki | 6.64 | DRUG MATRIX | |||||
Sex hormone-binding globulin | Secreted | Kd | 7.97 | CHEMBL | |||||
Androgen receptor | Nuclear hormone receptor | IC50 | 7.12 | WOMBAT-PK | |||||
Progesterone receptor | Transcription factor | Ki | 8.91 | DRUG MATRIX | |||||
Estrogen receptor | Transcription factor | Kd | 9.20 | CHEMBL | |||||
Androgen receptor | Transcription factor | IC50 | 6.92 | CHEMBL |
ID | Source |
---|---|
4018496 | VUID |
N0000146818 | NUI |
C0028356 | UMLSCUI |
D00182 | KEGG_DRUG |
63758001 | SNOMEDCT_US |
4018496 | VANDF |
7514 | RXNORM |
126102009 | SNOMEDCT_US |
5187 | MMSL |
d00555 | MMSL |
182290 | MMSL |
001298 | NDDF |
001326 | NDDF |
CHEBI:7627 | CHEBI |
CHEMBL1162 | ChEMBL_ID |
DB00717 | DRUGBANK_ID |
T18F433X4S | UNII |
687 | INN_ID |
6230 | PUBCHEM_CID |
D009640 | MESH_DESCRIPTOR_UI |
2880 | IUPHAR_LIGAND_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
GENERESS Fe | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0023-6030 | KIT | 0.80 mg | ORAL | NDA | 19 sections |
Norethindrone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7272 | TABLET | 0.35 mg | ORAL | ANDA | 13 sections |
NORETHINDRONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7292 | TABLET | 0.35 mg | ORAL | ANDA | 13 sections |
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7297 | KIT | 0.40 mg | None | ANDA | 19 sections |
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7308 | KIT | 0.80 mg | None | ANDA | 19 sections |
Nortrel | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9008 | KIT | 0.50 mg | None | ANDA | 14 sections |
Nortrel | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9009 | TABLET | 1 mg | ORAL | ANDA | 14 sections |
Nortrel | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9010 | KIT | 1 mg | None | ANDA | 14 sections |
Nortrel 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 0555-9012 | KIT | 0.75 mg | None | ANDA | 15 sections |
Nortrel 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 0555-9012 | KIT | 1 mg | None | ANDA | 15 sections |
Nortrel 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 0555-9012 | KIT | 0.50 mg | None | ANDA | 15 sections |
Balziva | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9034 | KIT | 0.40 mg | None | ANDA | 14 sections |
Aranelle | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0555-9066 | KIT | 1 mg | None | ANDA | 14 sections |
Aranelle | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0555-9066 | KIT | 0.50 mg | None | ANDA | 14 sections |
Cyclafem 1/35 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0603-7521 | KIT | 1 mg | None | ANDA | 16 sections |
Cyclafem 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 0603-7525 | KIT | 1 mg | None | ANDA | 16 sections |
Cyclafem 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 0603-7525 | KIT | 0.75 mg | None | ANDA | 16 sections |
Cyclafem 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 0603-7525 | KIT | 0.50 mg | None | ANDA | 16 sections |
Dasetta 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 16714-346 | KIT | 1 mg | ORAL | ANDA | 15 sections |
Dasetta 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 16714-346 | KIT | 0.50 mg | ORAL | ANDA | 15 sections |
Dasetta 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 6 | 16714-346 | KIT | 0.75 mg | ORAL | ANDA | 15 sections |
Philith | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-347 | KIT | 0.40 mg | ORAL | ANDA | 13 sections |
Dasetta 1/35 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-348 | KIT | 1 mg | ORAL | ANDA | 14 sections |
Wera | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-370 | KIT | 0.50 mg | ORAL | ANDA | 15 sections |
DEBLITANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-440 | KIT | 0.35 mg | None | ANDA | 14 sections |
SHAROBEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-441 | KIT | 0.35 mg | None | ANDA | 14 sections |
Necon | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-857 | KIT | 1 mg | None | ANDA | 13 sections |
Necon 0.5/35 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42254-287 | KIT | 0.50 mg | None | ANDA | 14 sections |
ALYACEN 1/35 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1477 | KIT | 1 mg | None | ANDA | 12 sections |
ALYACEN 7/7/7 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1478 | KIT | 0.50 mg | None | ANDA | 12 sections |